Andreas Du Bois

List of Publications by Year
in descending order

37 papers	9,158 citations	201385 27 h-index	315357 38 g-index
39 all docs	39 docs citations	39 times ranked	9678 citing authors

#	Article	IF	Citations
1	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	1.4	23
2	Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial. Cancers, 2022, 14, 1189.	1.7	3
3	Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era. British Journal of Cancer, 2022, 127, 79-83.	2.9	5
4	Cell-Free-DNA-Based Copy Number Index Score in Epithelial Ovarian Cancerâ€"Impact for Diagnosis and Treatment Monitoring. Cancers, 2022, 14, 168.	1.7	5
5	Identification of a Locus Near ULK1 Associated With Progression-Free Survival in Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1669-1680.	1.1	5
6	Ovarian Cancerâ€"Specific BRCA-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial. Clinical Cancer Research, 2021, 27, 6559-6569.	3.2	9
7	Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer. New England Journal of Medicine, 2021, 385, 2123-2131.	13.9	144
8	Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883). Journal of Medical Genetics, 2019, 56, 574-580.	1.5	34
9	Early treatment modifications improve chemotherapy adherence in ovarian cancer patients â‰¥70â€¯years. Gynecologic Oncology, 2019, 153, 616-624.	0.6	4
10	Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study. Clinical Cancer Research, 2019, 25, 5342-5350.	3.2	33
11	A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms. New England Journal of Medicine, 2019, 380, 822-832.	13.9	373
12	Pattern and impact of metastatic cardiophrenic lymph nodes in advanced epithelial ovarian cancer. Gynecologic Oncology, 2019, 152, 76-81.	0.6	32
13	Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1). PLoS ONE, 2017, 12, e0186043.	1.1	105
14	LION: Lymphadenectomy in ovarian neoplasmsâ€"A prospective randomized AGO study group led gynecologic cancer intergroup trial.. Journal of Clinical Oncology, 2017, 35, 5500-5500.	0.8	81
15	Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. New England Journal of Medicine, 2016, 375, 2154-2164.	13.9	1,860
16	Impact of Abdominal Wall Metastases on Prognosis in Epithelial Ovarian Cancer. International Journal of Gynecological Cancer, 2016, 26, 1594-1600.	1.2	23
17	FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisited. Gynecologic Oncology, 2016, 142, 597-607.	0.6	64
18	Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNAâ€"Expressing Platinum-Resistant Ovarian Cancer (PENELOPE). Journal of Clinical Oncology, 2016, 34, 2516-2525.	0.8	60

#	Article	IF	Citations
19	Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV. Gynecologic Oncology, 2016, 140, 215-220.	0.6	62
20	Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncology, The, 2016, 17, 78-89.	5.1	205
21	Surgical management of cardiophrenic lymph nodes in patients with advanced ovarian cancer. Gynecologic Oncology, 2016, 141, 271-275.	0.6	47
22	Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer. Oncotarget, 2016, 7, 6353-6368.	0.8	29
23	Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. Clinical Cancer Research, 2015, 21, 5264-5276.	3.2	33
24	Prognostic and predictive value of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) score in surgery for recurrent ovarian cancer. Gynecologic Oncology, 2014, 132, 537-541.	0.6	32
25	ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: A comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Gynecologic Oncology, 2013, 131, 8-14.	0.6	55
26	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nature Genetics, 2013, 45, 362-370.	9.4	326
27	Treatment of Elderly Ovarian Cancer Patients in the Context of Controlled Clinical Trials: A Joint Analysis of the AGO Germany Experience. Onkologie, 2012, 35, 76-81.	1.1	21
28	A Phase 3 Trial of Bevacizumab in Ovarian Cancer. New England Journal of Medicine, 2011, 365, 2484-2496.	13.9	1,843
29	Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG). International Journal of Gynecological Cancer, 2011, 21, 419-423.	1.2	500
30	Influence of Residual Tumor on Outcome in Ovarian Cancer Patients With FIGO Stage IV Disease. Annals of Surgical Oncology, 2010, 17, 1642-1648.	0.7	137
31	Phase III Trial of Carboplatin Plus Paclitaxel With or Without Gemcitabine in First-Line Treatment of Epithelial Ovarian Cancer. Journal of Clinical Oncology, 2010, 28, 4162-4169.	0.8	94
32	Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials. Cancer, 2009, 115, 1234-1244.	2.0	1,270
33	Impact of age on outcome in patients with advanced ovarian cancer treated within a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecologic Oncology, 2006, 100, 300-307.	0.6	50
34	Randomized Phase III Trial of Topotecan Following Carboplatin and Paclitaxel in First-line Treatment of Advanced Ovarian Cancer: A Gynecologic Cancer Intergroup Trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute, 2006, 98, 1036-1045.	3.0	189
35	Addition of Epirubicin As a Third Drug to Carboplatin-Paclitaxel in First-Line Treatment of Advanced Ovarian Cancer: A Prospectively Randomized Gynecologic Cancer Intergroup Trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. Journal of Clinical Oncology, 2006, 24, 1127-1135.	0.8	190
36	Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors (Ovarian Cancer). Journal of the National Cancer Institute, 2004, 96, 487-488.	3.0	258

#	Article	IF	Citations
37	A Randomized Clinical Trial of Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel as First-Line Treatment of Ovarian Cancer. Journal of the National Cancer Institute, 2003, 95, 1320-1329.	3.0	950